Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)

2018 ◽  
Vol 49 (1) ◽  
pp. 64-71 ◽  
Author(s):  
Yoshio Sumida ◽  
Kenta Murotani ◽  
Miyoko Saito ◽  
Atsuko Tamasawa ◽  
Yusuke Osonoi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Fat Content ◽  
Alcoholic Fatty Liver ◽  
Hepatic Fat ◽  
Alcoholic Fatty Liver Disease ◽  
Diabetes Patients

Dapagliflozin reduces hepatic and visceral fat in type‐2 diabetes patients with non‐alcoholic fatty liver disease

2021 ◽  
Author(s):  
Susrichit Phrueksotsai ◽  
Kanokwan Pinyopornpanish ◽  
Juntima Euathrongchit ◽  
Apinya Leerapun ◽  
Arintaya Phrommintikul ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Visceral Fat ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease ◽  
Diabetes Patients

scholarly journals Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Asieh Mansour ◽  
Mohammad Reza Mohajeri-Tehrani ◽  
Majid Samadi ◽  
Mostafa Qorbani ◽  
Shahin Merat ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Chlorogenic Acid ◽  
Fatty Liver Disease ◽  
Model Assessment ◽  
Alcoholic Fatty Liver ◽  
Hepatic Fat ◽  
Alcoholic Fatty Liver Disease

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is much more frequent and more severe, including cirrhosis, hepatocellular carcinoma in patients with type 2 diabetes. Coffee is a complex beverage with hundreds of compounds whereas caffeine and chlorogenic acid are the most abundant bioactive compounds. The published epidemiological data demonstrating beneficial associations between all categories of coffee exposure and ranges of liver outcomes are rapidly growing; however, the main contributors and cause-effect relationships have not yet been elucidated. To address existing knowledge gaps, we sought to determine the efficacy and safety of 6 months chlorogenic acid and/or caffeine supplementation in patients with type 2 diabetes affected by NAFLD. Methods This trial was carried out at two Diabetes Centers to assess the effects of supplementation with daily doses of 200 mg chlorogenic acid, 200 mg caffeine, 200 mg chlorogenic acid plus 200 mg caffeine or placebo (starch) in patients with type 2 diabetes and NAFLD. The primary endpoint was reduction of hepatic fat and stiffness measured by FibroScan, and changes in serum hepatic enzymes and cytokeratin − 18 (CK-18) levels. Secondary endpoints were improvements in metabolic (including fasting glucose, homeostasis model assessment-estimated insulin resistance (HOMA-IR), hemoglobin A1c (HBA1C), C-peptide, insulin and lipid profiles) and inflammatory (including nuclear factor k-B (NF-KB), tumor necrosis factor (TNF-α), high sensitive- C reactive protein(hs-CRP)) parameters from baseline to the end of treatment. Results Neither chlorogenic acid nor caffeine was superior to placebo in attenuation of the hepatic fat and stiffness and other hepatic outcomes in patients with diabetes and NAFLD. Except for the lower level of total cholesterol in caffeine group (p = 0.04), and higher level of insulin in chlorogenic acid plus caffeine group (p = 0.01) compared with placebo, there were no significant differences among the treatment groups. Conclusion These findings do not recommend caffeine and/or chlorogenic acid to treat NAFLD in type 2 diabetes patients. Trial registration IRCT201707024010N21. Registered 14 September 2017.

P 24: Non alcoholic fatty liver disease in type 2 diabetes patients

2012 ◽  
Vol 38 ◽  
pp. S113
Author(s):  
B. Idzior-Walus ◽  
A. Trojak ◽  
M.T. Małecki ◽  
M. Walus-Miarka ◽  
E. Wozniakiewicz
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease ◽  
Diabetes Patients

Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients

2019 ◽  
Vol 56 (11) ◽  
pp. 1199-1207 ◽  
Author(s):  
Asieh Mansour ◽  
Mohammad Reza Mohajeri-Tehrani ◽  
Majid Samadi ◽  
Hadis Gerami ◽  
Mostafa Qorbani ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Fibrosis ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease ◽  
Diabetes Patients
Sign in / Sign up

Export Citation Format

Share Document